REF/2011/08/ CTRI Website URL -
|
|
- Dominick Watts
- 7 years ago
- Views:
Transcription
1 Clinical Trial Details (PDF Generation Date :- Thu, 14 Jul :46:45 GMT) CTRI Number Last Modified On 06/11/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study Scientific Title of Study CTRI/2011/08/ [Registered on: 19/08/2011] - Trial Registered Prospectively No Interventional Vaccine Preventive Randomized, Parallel Group, Active Controlled Trial A STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBILs TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS. A PHASE III, RANDOMIZED, MULTICENTERIC, CONTROLLED STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBILs TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS. Secondary IDs if Any Secondary ID Identifier Details of Principal Investigator or overall Trial Coordinator (multi-center study) Details Contact Person (Scientific Query) Details Contact Person (Public Query) BBIL/CTP/04/2010 Designation Affiliation Protocol Number Details of Principal Investigator Dr Anit Singh Asst. Medical Director Phone Fax Designation Affiliation Bharat Biotech International Ltd Bharat Biotech International Ltd Genome Valley, Shameerpet Mandal Hyderabad, Andhra Pradesh Hyderabad India anits@bharatbiotech.com Details Contact Person (Scientific Query) Dr Anit Singh Asst. Medical Director Phone Fax Designation Affiliation Bharat Biotech International Ltd Bharat Biotech International Ltd Genome Valley, Shameerpet Mandal Hyderabad, Andhra Pradesh Hyderabad India anits@bharatbiotech.com Details Contact Person (Public Query) Dr Anit Singh Asst. Medical Director Bharat Biotech International Ltd Bharat Biotech International Ltd Genome Valley, Shameerpet Mandal Hyderabad, Andhra Pradesh Hyderabad page 1 / 8
2 Source of Monetary or Material Support Primary Sponsor Details of Secondary Sponsor Countries of Recruitment Sites of Study Details of Ethics Committee India Phone Fax Source of Monetary or Material Support > Bharat Biotech International Ltd Genome Valley, Shameerpet Mandal Hyderabad, Andhra Pradesh Type of Sponsor NIL List of Countries India of Principal Investigator Primary Sponsor Details Bharat Biotech International Ltd Bharat Biotech International Ltd Genome Valley, Shameerpet Mandal Hyderabad, Andhra Pradesh Pharmaceutical industry-indian NIL of Site Site Phone/Fax/ Dr Monjori Mitra Institute of Child Health Institute of Child, Health11Dr.Biresh Guha Street Kolkata WEST BENGAL Dr P Venugopal King George Hospital Department of pediatrics, KGH, Vishakapatnam Visakhapatnam DrBSudhaka Priya Children Hospital Dept of pediatrics Priya Children Hospital New P&T Colony,Patamata Krishna Dr Mukesh Gupta soumya Child Clinic soumya Child Clinic, Near Laxmi mandir Cinima, Tonk road Jaipur RAJASTHAN Dr J Bhuvaneshwar Rao Sri Srinivasa Children Hospital Sri Srinivasa Children Hospital, Pediatrics Chiluku Durgaya Street Nakala Road Krishna monjori.mitra@medclins earch.com venugopal_kgh@yahoo.com drbsudhakar@gmail.co m drmukeshgupta.pediatri cs@gmail.com jnvbrao@rediffmail.com of Committee Approval Status Date of Approval Is Independent Ethics Committee? Central Ethics Committee Approved 20/06/2011 Yes Institute of Child Health Approved 03/08/2011 No Institute of Preventive medicine Approved 07/05/2011 No page 2 / 8
3 Regulatory Clearance Status from DCGI Health Condition / Problems Studied Intervention / Comparator Agent Inclusion Criteria Institutional ethics committee,mahavir medical Research center Institutional Ethics Committee, King George Hospital Approved 29/08/2011 No Approved 09/04/2011 No KLE University Approved 22/09/2011 No Sanjeevini ethics committee Vishakapatnam Central Ethics Committee Status Approved 28/05/2011 Yes Approved 20/06/2011 Yes Date Approved/Obtained 09/08/2011 Health Type Healthy Human Volunteers Condition To prevent Typhoid Type Details Comparator Agent TYPBAR Typhoid Vi capsular polysaccharide vaccine (TYPBAR) administered as one dose of 0.5 ml in all age Reference groups by intramuscular route. Intervention TYPHOID TT Vaccine Typhoid Vi capsular polysaccharide-tt protein conjugate vaccine manufactured by Bharat Biotech international Limited, Hyderabad. Administered as one dose of 0.5 ml in all age Test groups by intramuscular route. Age From Age To Gender Details 6.00 Month(s) Year(s) Both Inclusion Criteria 1. Provide voluntary written and signed informed consent from volunteer or if minor from parent/legal guardian. 2. Healthy subjects in two cohorts aged 6 to 24 months, and 2-45 years. 3. Are not participating in or plan to participate in another research during the next three months & be available throughout study period. 4. Family does not plan to move during the study period, and housed not further that 50 Km away from the study site. Exclusion Criteria Details Exclusion Criteria Fever of any origin or infections more than 3 days within one month prior to screening or on the day of screening 2) Any confirmed or suspected immunosuppressive condition. 3) Any treatment with immunosuppressive or immunostimulant therapy 4) Use of any marketed or investigational or herbal medicine or non-registered drug or vaccine for typhoid. 5) Life threatening or serious cardiac (NYHA grade 3&4), respiratory, gastrointestinal, hepatic, renal, endocrine and systemic disorders. page 3 / 8
4 6) Have been vaccinated against typhoid fever or had exposure to typhoid fever within the last three years. Method of Generating Random Sequence Method of Concealment Blinding/Masking Stratified block randomization An Open list of random numbers Open Label Primary Outcome Outcome Timepoints The comparative assessment of the immunogenicity of the test vaccine (conjugate typhoid vaccine) versus the comparator (polysaccharide typhoid vaccine) by estimation of: 1. 4 fold Seroconversion rates in each treatment arm at 6 weeks post vaccination fold Seroconversion rate in Cohort-1(2 years) from base line to 6 weeks post vaccination. 3. Extent of rise of anti Vi IgG antibody from baseline values to 6 weeks post vaccination The comparative assessment of the immunogenicity of the test vaccine (conjugate typhoid vaccine) versus the comparator (polysaccharide typhoid vaccine) by estimation of: 1. 4 fold Seroconversion rates in each treatment arm at 6 weeks post vaccination fold Seroconversion rate in Cohort-1(2 years) from base line to 6 weeks post vaccination. 3. Extent of rise of anti Vi IgG antibody from baseline values to 6 weeks post vaccination Secondary Outcome Outcome Timepoints 1. Comparative assessment of safety and tolerability of the vaccine in all subjects up to 3 months post vaccination. 2. Based on the Geometric Mean Titers of the primary objectives 1& 2 the superiority of test over reference vaccine will be determined 3 months Target Sample Size Phase of Trial Phase 3 Date of First Enrollment (India) Date of First Enrollment (Global) Estimated Duration of Trial Recruitment Status of Trial (Global) Recruitment Status of Trial (India) Publication Details Total Sample Size=981 Sample Size from India=981 12/09/2011 No Date Specified Years=1 Months=0 Days=0 Not Applicable Completed Cohort Age group Vaccine Groups Total TEST REFERENCE page 4 / 8
5 1?6 months to?2 years >2 years to?45 years Total 981 The null hypothesis for the study assumes that the mean seroconversion rate (i.e a 4 fold rise of anti- Vi IgG antibody titer from baseline ) in the test group (? T ) and the control group (? C ) are equal i.e? T =? C and the alternate hypothesis is that they are not equal i.e? T?? C. The proposed sample size has been calculated on the basis of information from previous studies where the conjugate vaccine has demonstrated a seroconversion rate of about 80%. Therefore assuming an effect size in seroconversion rates as 10%,? of 0.05 and 80% power and equal allocation rates in both arms, the number of evaluable subjects required per group would be 294. If we assume a 10% drop out rate- evaluable subjects per group would be required i.e a total of 327. The sample size has been calculated using the Statistical software version 6. In the group <2 years we propose to recruit 327. Total sample size proposed for the study would be 981. Cohort-1: 327 (subjects aged?6months to?2 years Open Labeled, single arm). Cohort-2: 654 (subjects aged >2 years to?45 years- Double Blinded, two arms with equal allocation ratio). Note-1: The comparator vaccine is a polysaccharide vaccine which has T-cell independent nature of immune response and is not effective below 2 years and hence not approved for use in this age group. Also we examine other vaccines which could be used as comparator vaccine in below 2 years age group. The other vaccines which could be given in the control arm of this group would be different in the various stratified age range based on the Expanded Program on Immunization (EPI)/Indian Academy of Pediatrics (IAP) vaccine schedule leading to complexity of the study design and also statistical analysis. Considering all these issues this group (Cohort-1) would be single arm, an open labeled study. page 5 / 8
6 Note-2: The number of the subjects in Cohort-2 enrolled would be more (~400 subjects) in <15 years age group and less (~254 subjects) in >15 years because the common age group of getting typhoid fever is 2-15 years. he Subjects will be randomly assigned to test vaccine or Reference vaccine group as per the codes generated by the computer program. A copy of computer generated randomization list of subject numbers will be maintained by study member located at the center. The blinding key or decoding list of randomization will be provided to statistician at the time of statistical analysis by Asian Clinical Trials, Hyderabad. Services such as generation of randomization list, labeling of vials, blinding and generation of decoding list or envelops will be provided by the Asian Clinical Trials, Hyderabad. To evaluate the Safety and Immunogenicity of Typhoid Vi capsular polysaccharide-tt protein conjugate vaccine Vs Reference vaccine in healthy subjects. The comparative assessment of the immunogenicity of the test vaccine (conjugate typhoid vaccine) versus the comparator (polysaccharide typhoid vaccine) by estimation of: 1. 4 fold Seroconversion rates in each treatment arm at 6 weeks post vaccination fold Seroconversion rate in Cohort-1(<2 years) from base line to 6 weeks post vaccination. 3. Extent of rise of anti Vi IgG antibody from baseline values to 6 weeks post vaccination. 1. Comparative assessment of safety and tolerability of the vaccine in all subjects up to 3 months post vaccination. 2. Based on the Geometric Mean Titers of the primary objectives 1& 2 the superiority of test over reference vaccine will be determined. Typhoid fever is a very common and serious disease in developing countries like India. Salmonella typhi, the bacteria responsible to typhoid fever has become resistant to various antibiotics with raising concern. Methods to control typhoid fever, such as sanitary water and food supply alone with effective sewage treatment are not likely to be available in these countries in near future. page 6 / 8
7 The use of effective and safe vaccine especially in children could lessen the incidence of disease in endemic areas. The currently licensed vaccines have various limitations 1) Most of these vaccines have a efficacy of only 70 %, 2) Orally administered attenuated Ty21a requires at least three doses and has a low rate of efficacy in area with a high incidence of typhoid fever and its efficacy has not been demonstrated in children. 3) Parenterally administered vaccines are an age dependent serum antibody response and reinjection did not elicit a booster response (T-cell independent). To overcome the above limitations Vi polysaccharide has been conjugated with tetanus toxoid protein, this conjugation technique has been developed by Bharat Biotech. The new vaccine has a higher immunogenicity response and is T-cell dependent. All previous typhoid conjugate vaccines clinical studies have shown that the efficacy and immunogenicity of Typhoid conjugate 8, 9, 10. vaccine are higher than Vi polysaccharide vaccine alone This vaccine has already undergone the safety, immunogenicity and dose ranging studies in children 2 to 17 years in Phase II. The results suggest that the vaccine was absolutely safe, potent to produce an immune response to protect against Typhoid. The vaccine is efficacious to induce antibody titers required to protect for Typhoid disease and also superior to already registered commercially available Vi Capsular Polysaccharide vaccine. The single dose of 25?g/0.5mL Typhoid-TT conjugate vaccine showed adequate immune response, when compared to two doses of 25?g/ 0.5mL and two doses of 15?g/0.5mL dose of vaccine response and there is no significant difference between the groups. Hence the current study is to be undertaken to demonstrate the Immunogenicity and Safety of the new conjugate vaccine in the dosage of 25?g/0.5mL as single dose to diverse healthy population of age?6 months to?2 yrs, and? 2yrs to? 45 yrs. Data analysis will be performed by Indian Statistical Institute, Hyderabad / Medclin Research Kolkata. The data from various trial centers would be collected by representatives of Bharat Biotech after reviewing it at the site. The pre-vaccination geometric mean antibody (anti Vi anti IgG) titer at baseline will be compared with the 6 weeks post vaccination titers for detecting any statistically significant differences. The level of significance for the GMT analysis in both the arm will be considered as p<0.05 and the 95% CI for GMT. The mean of pre as well as post immunization antibody levels will be compared between two groups by Kruskal Wallis test. Repeated measure antibody levels in each group will be compared with the respective mean pre-immunization antibody levels by Friedman s ANOVA test. The mean seroconversion rate in each group will be calculated and between group comparisons will be done using Chi Square test or Fisher s exact test. The 95% CI will also be computed and values of p<0.05 will be considered statistically significant. page 7 / 8
8 Powered by TCPDF ( REF/2011/08/ The safety data will be described as the percentage of subjects presenting with each of the local and systemic reactions and comparisons will be made between the two groups using chi-square test or Fisher s exact tests. The 95% CI will also be computed and values of p<0.05 will be considered statistically significant. page 8 / 8
REF/2011/03/002226 CTRI Website URL - http://ctri.nic.in
Clinical Trial Details (PDF Generation Date :- Thu, 14 Jul 2016 15:20:58 GMT) CTRI Number Last Modified On 28/01/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationREF/2011/06/002450 CTRI Website URL - http://ctri.nic.in
Clinical Trial Details (PDF Generation Date :- Thu, 14 Jul 2016 07:52:01 GMT) CTRI Number Last Modified On 08/07/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationMantoux testing is not performed in the clinic on a Thursday, as it would need to be read on a Sunday, when we are closed.
VACCINE SCHEDULES The vaccine schedules detailed below are those recommended by the vaccine manufacturers. Many vaccines can be given at short notice or schedules shortened to accommodate your travel plans.
More informationTrial Description. Organizational Data. Secondary IDs
Trial Description Title A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationTravel Vaccine Schedule
Travel Vaccine Schedule This table acts as a quick guide to vaccine schedules. The Summary of Product Characteristics should always be referred to for more detailed information. Vaccine Cholera Dukoral
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationCONTROL AND PREVENTION OF ENTERIC FEVER: POLICY AND PRACTICE IN WHO SEARO
CONTROL AND PREVENTION OF ENTERIC FEVER: POLICY AND PRACTICE IN WHO SEARO Professor Lalitha Mendis 8 th International Conference on Typhoid fever And Other Invasive Salmonelloses 1-2 March 2013 WHO Position
More informationDiagnosis, Treatment and Prevention of Typhoid Fever in the Children of Bangladesh: A Microbiologist s View.
Diagnosis, Treatment and Prevention of Typhoid Fever in the Children of Bangladesh: A Microbiologist s View. Samir K Saha, Ph.D. Department of Microbiology Dhaka Shishu Hospital Bangladesh Typhoid Fever:Salmonella
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationTUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011
TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued
More informationVACCINE SCHEDULES. Vaccination Vaccine Type Contraindications Schedule Other information. Those who have already had a BCG vaccine.
VACCINE SCHEDULES The vaccine schedules detailed below are those recommended by the vaccine manufacturers. Many vaccines can be given at short notice or schedules shortened to accommodate your travel plans.
More informationMedia Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com
News Release FOR IMMEDIATE RELEASE Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 annick.robinson@merck.com Merck's HPV Vaccine, GARDASIL 9, now available
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationProspects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
More informationMain Changes to the Vaccination Schedule Recommended by the Japan Pediatric Society January 12, 2014
Main Changes to the Vaccination Schedule Recommended by the Japan Pediatric Society January, 04 ) 3-valent Pneumococcal conjugate vaccine (PCV3) The description of catch-up schedule for PCV3 has been revised
More informationPRE-EMPLOYMENT SCREENING AND IMMUNIZATION DOCUMENTATION
Page 185 PRE-EMPLOYMENT SCREENING AND IMMUNIZATION DOCUMENTATION In order to protect the health of all residents/fellows, employees and patients, and in order to comply with CDC guidelines and immunization
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationTBE vaccines: immunogenicity, effectiveness and safety
TBE vaccines: immunogenicity, effectiveness and safety Prof. H.Kollaritsch, MD., DTM., Associate professor for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology,
More informationHuman Clinical Study for Free Testosterone & Muscle Mass Boosting
Human Clinical Study for Free Testosterone & Muscle Mass Boosting GE Nutrients, Inc. 920 E. Orangethorpe Avenue, Suite B Anaheim, California 92801, USA Phone: +1-714-870-8723 Fax: +1-732-875-0306 Contact
More informationBiostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another
More informationChapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
More informationPentavalent Vaccine. Guide for Health Workers. with Answers to Frequently Asked Questions
Pentavalent Vaccine Guide for Health Workers with Answers to Frequently Asked Questions Ministry of Health and Family Welfare Government of India 2012 Immunization is one of the most well-known and effective
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationIMMUNIZATION IN SPECIAL SITUATIONS
143 IMMUNIZATION IN SPECIAL SITUATIONS Immunization in preterm/low birth weight infants In principle, all vaccines may be administered as per schedule according to the chronological age irrespective of
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationEFFECT OF DAILY VERSUS WEEKLY IRON FOLIC ACID SUPPLEMENTATION ON THE HAEMOGLOBIN LEVELS OF CHILDREN 6 TO 36 MONTHS OF URBAN SLUMS OF VADODARA
ORIGINAL ARTICLE. EFFECT OF DAILY VERSUS WEEKLY IRON FOLIC ACID SUPPLEMENTATION ON THE HAEMOGLOBIN LEVELS OF CHILDREN 6 TO 36 MONTHS OF URBAN SLUMS OF VADODARA K Sharma 1, P Parikh 2, F Desai 3 1 PhD Advisor,
More informationALBERTA IMMUNIZATION POLICY GUIDELINES
ALBERTA IMMUNIZATION POLICY GUIDELINES Hepatitis Vaccines. Hepatitis A Vaccines Refer to the vaccine product monograph and the Canadian Immunization Guide for further Product monographs are available on
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationDopaminergic and cholinergic modulation of oculomotor control during saccades
Trial Description Title Dopaminergic and cholinergic modulation of oculomotor control during saccades Trial Acronym URL of the trial Brief Summary in Lay Language In this basic science study we investigate
More information160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.
160S01105, Page 1 of 7 New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationA Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
More informationResource Document 6: Tetanus Immunization. I. Introduction
Resource Document 6: Tetanus Immunization I. Introduction Attention must be directed to adequate tetanus prophylaxis in the multiply injured patient, particularly if open-extremity trauma is present. The
More informationCore Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationWhy use passive immunity?
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationNHS FORTH VALLEY Guidelines for Hepatitis B Vaccination in High Risk Groups
NHS FORTH VALLEY Guidelines for Hepatitis B Vaccination in High Risk Groups Approved 01/04/2012 Version 1.0 Date of First Issue 01/04/2012 Review Date 01/02/2014 Date of Issue 01/04/2012 EQIA Yes Author
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationInvestigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
More informationImmunization Information for Blinn College Students
1 Immunization Information for Blinn College Students *Important Information Regarding the Bacterial Meningitis Vaccine* The State passed Senate Bill 1107 in 2011 and recently Senate Bill 62 in 2013, which
More informationI B2.4. Design of the patient information leaflet for VariQuin
(English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More information10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationRe: LUMIGAN 0.03% (bimatoprost ophthalmic solution 0.03%) and LUMIGAN 0.01% (bimatoprost ophthalmic solution 0.01%)
Allergan Ltd, 1st Floor, Marlow International, Parkway, Marlow, Bucks SL7 1YL Tel: (01628) 494444 Facsimile: (01628) 494449 Ref No: UK15-000677 Mandeep Allingham NW Surrey CCG February 18, 2015 Dear Ms
More informationAssertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia
Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia Peter Higgs, Nyree Chung, Shelley Cogger, Rebecca Winter, Margaret Hellard & Paul Dietze Acknowledgements
More informationFirst In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
More informationA Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis
A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationWilliam Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016
William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15
More informationStudy Designs. Simon Day, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBlood donation awareness and beliefs among medical and nursing students
Research Article Blood donation awareness and beliefs among medical and nursing students Suchetha Singh, Muninarayana Chandrappa, Mahesh Venkatesha, Anil NS Department of Community Medicine, Sri Devaraj
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationFDA Update on the H1N1 Flu Vaccine and Antiviral Medications
FDA Update on the H1N1 Flu Vaccine and Antiviral Medications Beth Fabian Fritsch, R.Ph., M.B.A. Commander, U.S. Public Health Service Health Programs Coordinator Office of Special Health Issues Food and
More informationXXXXXXX. See 17 for PATIENT COUNSELING INFORMATION. Revised: XX/XXXX
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VAQTA safely and effectively. See full prescribing information for VAQTA. VAQTA () Suspension for
More informationHaemophilus influenzaetype b (Hib) Vaccination Position Paper. July 2013
Haemophilus influenzaetype b (Hib) Vaccination Position Paper July 2013 Hib burden-pre vaccine era In 2000, before widespread introduction of Hib vaccine in resource-poor countries, Hib caused: 8.13 million
More informationFAQs on Influenza A (H1N1-2009) Vaccine
FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from
More informationAdvancing research: a physician s guide to clinical trials
Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer
More informationGENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
More informationRevised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14)
Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14) Documents to be submitted for grant of permission to conduct BA/BE studies in Human Subjects/Patients
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More informationCLINICAL RESEARCH PROTOCOL CHECKLIST
CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationFURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES
FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES Dr Alison Jones Great Ormond Street Hospital for Children NHS Trust London WC1N 3JH United Kingdom
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationCHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY
CHAPTER 8 IMMUNOLOGICAL IMPLICATIONS OF PEPTIDE CARBOHYDRATE MIMICRY Immunological Implications of Peptide-Carbohydrate Mimicry 8.1 Introduction The two chemically dissimilar molecules, a peptide (12mer)
More informationCore Training Outline
Core Training Outline Modules: 1) Study Design 2) PI Oversight 3) Financial Management 4) Study Operations 5) Recruitment & Retention 6) Informed Consent 7) Investigational Products 8) Subject Safety 9)
More informationCourse Curriculum for Master Degree in Clinical Pharmacy
Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon
More informationSanofi Pasteur 095 - ActHIB LE6677
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ActHIB safely and effectively. See full prescribing information for ActHIB. ActHIB Haemophilus b
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNurse Aide Training Program Application Checklist
Nurse Aide Training Program Application Checklist The following checklist must be completed before enrolling in the Nurse Aide Training course: Complete, sign, and date the Application Form Have the physical
More informationFocus on Preventing Disease. keeping an eye on a healthy bottom line. Cattle Industry
Focus on Preventing Disease keeping an eye on a healthy bottom line Cattle Industry Multimin + VACCINES : University OF FLORIDA study data Study 1 Effect of injectable trace minerals on the humoral immune
More information10:20 11:30 Roundtable discussion: the role of biostatistics in advancing medicine and improving health; career as a biostatistician Monday
SUMMER INSTITUTE FOR TRAINING IN BIOSTATISTICS (SIBS) Week 1: Epidemiology, Data, and Statistical Software 10:00 10:15 Welcome and Introduction 10:20 11:30 Roundtable discussion: the role of biostatistics
More informationCenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
More informationAppendix 7.5: Immunization for Children Expecting Solid Organ Transplant after 18 Months of Age (Catch-up and Ongoing Schedule)
Appendix 7.5: Immunization for Children Expecting Solid Organ Transplant after 18 Months of Age (Catch-up and Ongoing Schedule) Revision Date: September 5, 2014 Note: These guidelines are intended as a
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAre Booster Doses of Hepatitis B Vaccine Necessary?
Are Booster Doses of Hepatitis B Vaccine Necessary? Current CDC Recommendations And Gaps in Knowledge Division of Viral Hepatitis Centers for Disease Control and Prevention, USA Current United States Recommendations
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationClinical trials in haemophilia
Clinical trials in haemophilia Dr. Paul Giangrande Oxford Haemophilia and Thrombosis Centre & Nuffield Department of Clinical Medicine University of Oxford paul.giangrande@ndm.ox.ac.uk Why do clinical
More informationReport of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis)
Report of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis) Date: February 18, 2014 H. A. Vahl, H. Bekman and J. van Riel Introduction: Substantial percentages of antibiotics applied in
More informationBIOAVAILABILITY & BIOEQUIVALENCE TRIALS
BIOAVAILABILITY & BIOEQUIVALENCE TRIALS Shubha Rani,, Ph.D. Technical Director & Head-Biometrics and Data Management Synchron Research Services Pvt. Ltd. Ahmedabad 380 054 drshubha@synchronresearch.com
More informationPATIENT INFORMATION SHEET KEY FACTS
PATIENT INFORMATION SHEET KEY FACTS Please read this carefully and refer to the full information sheet You are invited to take part in a research study, comparing subcutaneously (injection under skin)
More informationWENTWORTH INSTITUTE OF TECHNOLOGY ENTRANCE IMMUNIZATION FORM
WENTWORTH INSTITUTE OF TECHNOLOGY ENTRANCE IMMUNIZATION FORM Dear Student, Congratulations on your acceptance to Wentworth Institute of Technology! This letter describes the immunization requirements for
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationTreatment for. Malaria: DHA/PQP. Science Day MMV Stakeholders Meeting. Defeating Malaria Together 1
ANewOnce-a-day Treatment for Uncomplicated Malaria: DHA/PQP Science Day MMV Stakeholders Meeting Dr. Ambrose Talisuna Former Director Global Access, MMV & Field Coordinator, African Eurartesim Registration
More informationModule 7 Expanded Programme of Immunization (EPI)
Module 7 Expanded Programme of Immunization (EPI) (including Vitamin A, Tetanus Toxoid and Growth Monitoring) CONTENTS 7.1 What are the tools used for data collection?....................................2
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More information